This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Genomic Health Announces Presentation Of Oncotype DXA® Studies At The 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)

Stocks in this article: GHDX

REDWOOD CITY, Calif., Dec. 4, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from multiple Oncotype DX® breast cancer test studies at the 36 th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), being held December 10-14, 2013 at the Henry B. Gonzalez Convention Center. Presentations include results from a comparison of risk classification between the Oncotype DX breast cancer test and other genomic assays.


Thursday, December 12, 2013

  • Abstract: P3-05-08 Poster Session 3: "Discordance in hormone receptor (HR) assessment by IHC and RT-PCR in an estrogen receptor (ER) low-positive group (1-10% positive cells): Does accurate assessment of HR status require dual testing?" Authors: Singh B, Ziguridis N, Axelrod D, Butler SM, Jamshidian F, Charbavaz DB, Sing AP, Baehner FL Location: Exhibit Halls A-B Time: 5–7 p.m.

Saturday, December 14, 2013

  • Abstract: P6-05-11 Poster Session 6: "Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine" Authors: Harbeck N, Gluz O, Kreipe HH, Christgen M, Svedman C, Shak S, Hofmann D, Kuemmel S, Nuding B, Rezai M, Schumacher C, Kusche M, Forstbauer H, Maass N, Kraemer S, Aktas B, Mohrmann S, Wuerstlein R, Kates RE, Nitz U Location: Exhibit Hall C Time: 7:30–9 a.m.
  • Abstract: P6-06-02 Poster Session 6: "Direct comparison of risk classification between MammaPrint ®, Oncotype DX ® and MammoStrat ® assays in patients with early stage breast cancer" Authors: Shivers SC, Clark L, Esposito N, Howard N, King J, Acs G, Ellis D, Vrcelj V, Zanchi A, Stork-Sloots L, de Snoo F, Baehner FL, Butler SM, Jamshadian F, Sing AP, Blumencranz PW, Cox CE Location: Exhibit Hall C Time: 7:30–9 a.m.

To learn more about the Oncotype DX tests, SABCS attendees can visit Genomic Health's booth #409.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs